Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis.

Dubinsky, Marla C; Charles, Lorna; Selmaj, Krzysztof W; Comi, Giancarlo; Krakovich, Anthony; Rosen, Melissa; van der Woude, C Janneke; Mahadevan, Uma

Dubinsky, Marla C; Charles, Lorna; Selmaj, Krzysztof W; Comi, Giancarlo; Krakovich, Anthony; Rosen, Melissa; van der Woude, C Janneke; Mahadevan, Uma.

Afiliación

Dubinsky MC; Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Charles L; Bristol Myers Squibb, Princeton, NJ, USA.
Selmaj KW; Center for Neurology, Lodz, Poland.
Comi G; Department of Neurology, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.
Krakovich A; Department of Neurorehabilitation Sciences, Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy.
Rosen M; Bristol Myers Squibb, Princeton, NJ, USA.
van der Woude CJ; Bristol Myers Squibb, Princeton, NJ, USA.
Mahadevan U; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands.

Inflamm Bowel Dis ; 2024 Jan 24.

Article en En | MEDLINE | ID: mdl-38267826

This study evaluated pregnancy outcomes in patients with ulcerative colitis, Crohn's disease, or multiple sclerosis and in healthy volunteers treated with ozanimod. There was no increased incidence of fetal abnormalities or adverse pregnancy outcomes with ozanimod exposure during early pregnancy.

Palabras clave

Crohn's disease; multiple sclerosis; ozanimod; pregnancy; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Inflamm Bowel Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google